Description Results NMA

death, MI, recurrent ischaemia, use of Gp2b3a inhibitor 0.58 [0.34; 0.99]

death, MI 0.56 [0.30; 1.04]

TIMI major or minor bleeding not related to CABG 1.26 [0.63; 2.52]

Thrombotic complication during PCI 1.44 [0.59; 3.52]

otamixaban 5 doses (0·08 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) (n=2792)

vs.

Heparin+eptifibatide (n=449)

6 arms phase 2: otamixaban 5 doses (0·08 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) and unfractionated heparin + eptifi batide

double blind

Parallel groups

Sample size: 2792/449

Primary endpoint: death, MI, recurrent ischaemia, use of Gp2b3a

FU duration: 7 days

dose finding study